Healthcare issues related to clinical laboratories; H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests; Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests; Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests; H.R. 6202, the Telehealth Extension Act, and S. 3593, the Telehealth Extension and Evaluation Act, provisions relating to extension of Medicare coverage of telehealth services and limitations on payment for certain laboratory tests; S. 3534, the Tracking Pathogens Act, provisions relating to genomic sequencing of variants of the SARS-CoV-2 virus; S. 3799, the PREVENT Pandemics Act, and a draft of the Improving DATA in Public Health Act, provisions relating to demographic data reporting obligations for laboratories; Federal policy related to the National Correct Coding Initiative and manual instructions inconsistent with American Medical Association guidelines for Current Procedural Terminology (CPT) coding; H.R. 2144, the Access to Genetic Counselor Services Act, provisions relating to Medicare coverage of genetic counselor services; H.R. 4144/S. 2022, the Ending the Diagnostic Odyssey Act, provisions relating to coverage of whole genome sequencing services for certain individuals; H.R. 5030/S. 2706, the DIVERSE Trials Act, provisions relating to enhancing diversity in clinical trials and data collection and reporting by clinical laboratories; Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 6000, the Cures 2.0 Act, provisions relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing; H.R. 4144/S. 2022, the Ending the Diagnostic Odyssey Act, provisions relating to coverage of whole genome sequencing services for certain individuals; and H.R. 6875, the Right Drug Dose Now Act, provisions relating to use of pharmacogenetic information; H.R. 2565/S. 2952, the FDA Modernization Act, provisions relating to biomedical research; and Federal policy relating to CDC funding for standardization of pediatric reference range intervals and laboratory result harmonization. DOT Implementation of statutes 49 U.S.C. 41310(A), 49 U.S.C. 44902(B), 49 U.S.C. 41501, and 49 U.S.C. 41704, relating to cargo transport. Federal policy, and potential solutions, relating to supply chain disruptions resulting from Chinas implementation of sanitary and phytosanitary (SPS) measures in violation of the U.S.-China Phase One Deal and Chinas World Trade Organization obligations.
HCR - Health Issues TRA - Transportation TRD - Trade (domestic/foreign)
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 11 - Executive Office of the President (EOP) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 22 - U.S. Trade Representative (USTR)
LABORATORY CORPORATION OF AMERICA HOLDINGS
531 South Spring Street, Burlington, NC, 27215, US
KATHERINE PREGEL DONALD HORTON KATHERINE PREGEL DONALD HORTON KATHERINE PREGEL DONALD HORTON